secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001140361-22-044533
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics stockholders approve all proposals at 2022 annual meeting
-------------------------------------------------------------------------------

- All 11 director nominees elected; each received >16.6M votes for.
- Ratified Cherry Bekaert LLP as independent auditor for FY2022 (36.3M for).
- Approved issuance of up to 20M shares (max $60M principal) under Uihlein line of credit.
- Non-binding advisory resolution on executive compensation passed (16.3M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122044533/0001140361-22-044533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122044533/brhc10045110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer